General Information of Drug (ID: DMD3C21)

Drug Name
GBT021601
Synonyms
Osivelotor; GBT-601; GBT021601; GBT-021601; 2417955-18-9; osivelotor [INN]; 2-hydroxy-6-({(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl}methoxy)benzaldehyde; 2-hydroxy-6-[[(3S)-4-[2-(2-hydroxyethyl)pyridine-3-carbonyl]morpholin-3-yl]methoxy]benzaldehyde; SCHEMBL21957946; GTPL12856; UK749B4S16; example 8 [US20210047309]; HY-148788; CS-0641066; 2-hydroxy-6-{[(3S)-4-{[2-(2-hydroxyethyl)pyridin-3- yl]carbonyl}morpholin-3-yl]methoxy}benzaldehyde
Indication
Disease Entry ICD 11 Status REF
Sickle-cell disorder 3A51 Phase 2/3 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C20H22N2O6
Canonical SMILES
C1COCC(N1C(=O)C2=C(N=CC=C2)CCO)COC3=CC=CC(=C3C=O)O
InChI
InChI=1S/C20H22N2O6/c23-9-6-17-15(3-2-7-21-17)20(26)22-8-10-27-12-14(22)13-28-19-5-1-4-18(25)16(19)11-24/h1-5,7,11,14,23,25H,6,8-10,12-13H2/t14-/m0/s1
InChIKey
NIWBSQAKKNNWBT-AWEZNQCLSA-N
Cross-matching ID
PubChem CID
146567655
UNII
UK749B4S16
DrugBank ID
DB18071
TTD ID
DWR4I7

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hemoglobin (HB) TTQO71U HBA_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05632354) An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial. U.S.National Institutes of Health.
2 GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.